✨ Free AI Report
Sun Pharmaceutical Industries Limited: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Sun Pharmaceutical Industries Limited
Company Research

Sun Pharmaceutical Industries Limited: Business Overview, Financials & Competitive Analysis

Sun Pharmaceutical Industries Limited manufactures, develops, and markets branded and generic formulations and Active Pharmaceutical Ingredients (APIs), and is the largest pharmaceutical company in India. The company ...

Analyst-debate audio for Sun Pharmaceutical Industries Limited

AskCyborg analysts argue the bull and bear cases for Sun Pharmaceutical Industries Limited across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Solid

Cyborg Score thesis

Balanced multinational pharma with India market leadership and emerging markets momentum, offset by US generic pressures and...

Read the full analyst-debate transcript →
Industry Generic Drugs
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Sun Pharmaceutical Industries Limited Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Sun Pharmaceutical Industries Limited Overview

Pro stress-test →

Sun Pharmaceutical Industries Limited manufactures, develops, and markets branded and generic formulations and Active Pharmaceutical Ingredients (APIs), and is the largest pharmaceutical company in India. The company reported consolidated revenues of ₹582 billion for FY26 (year ended March 31, 2026), growing 11.9% year-on-year.

Strategic Profile

Pro stress-test →

Sun Pharma's diversified business mix—including India formulations (33% of revenue), emerging markets, US generics, and specialty medicines—enables balanced growth, with the company maintaining 8.4% market share as India's leading pharmaceutical player. The company is expanding its innovative product portfolio with US launches (Unloxcyt) and India introductions (Ilumya) to drive differentiated therapy offerings.

Competitive Landscape

Pro stress-test →

Sun Pharma competes in global generic pharmaceuticals and specialty medicines against international majors and regional peers. In India, it holds the #1 market position with 8.4% share; in the US, it faces pricing pressure on generics from competitors; in emerging markets, it has outpaced regional peers with 21.6% growth in formulations (Q3 FY26).

Industry Context

Sun Pharmaceutical Industries Limited operates in Generic Drugs.

Key facts

Founded: 1993 · Headquarters: Mumbai, India · Employees: ~16,436 · Revenue: ₹582 billion (FY26) · Market cap: ₹4.57 trillion (approx.)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Sun Pharmaceutical Industries Limited.

  • India formulation business growing 14% and contributing 33% of consolidated revenue, with Sun Pharma holding the #1 position and 8.4% market share in India's ₹2,407 billion pharma market as of March 2026.
  • Emerging markets sales grew 13.6% to US$1,265 million in FY26, offsetting flat US generics (down 0.9%).
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026FY26 revenue grew 11.9% to ₹582 billion; EBITDA up 16.1%; net profit up 5% to ₹115 billion.
  • January 2026Q3 FY26 revenue grew 15.1% to ₹154.7 billion; net profit up 16% YoY on strong branded business and new product launches.
  • +1 moreTrack every material event for Sun Pharmaceutical Industries Limited as it happens. Explore monitoring →
Get alerted when Sun Pharmaceutical Industries Limited has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CiplaLarge-cap Indian pharma competitor in generics, branded, and specialty medicines→LupinIndian multinational pharma with generics and specialty focus→Dr. Reddy'sIndian pharma multinational competing in generics and APIs→AurobindoIndian pharma competitor in injectables, generics, and APIs→

Compare Sun Pharmaceutical Industries Limited with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Sun Pharmaceutical Industries Limited operates in Generic Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Generic Drugs research →
NEW · MCP server

Ask your AI assistant about Sun Pharmaceutical Industries Limited

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Sun Pharmaceutical Industries Limited and its top competitor on Cyborg Score”
“What did Sun Pharmaceutical Industries Limited do this quarter?”
“Is Sun Pharmaceutical Industries Limited a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Sun Pharmaceutical Industries Limited do?+
Sun Pharmaceutical Industries Limited manufactures, develops, and markets branded and generic formulations and Active Pharmaceutical Ingredients (APIs), and is the largest pharmaceutical company in India. The company ...
What is Sun Pharmaceutical Industries Limited's Cyborg Score?+
Sun Pharmaceutical Industries Limited has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Sun Pharmaceutical Industries Limited's main competitors?+
Named competitors include Cipla, Lupin, Dr. Reddy's, Aurobindo. The full competitive landscape is in the AskCyborg report.
How can I get the full Sun Pharmaceutical Industries Limited research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Sun Pharmaceutical Industries Limited research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Sun Pharmaceutical Industries Limited over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Generic Drugs research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Cipla Limited7Lupin Limited